BNP Paribas Arbitrage SA lifted its position in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 48.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,123 shares of the company’s stock after purchasing an additional 7,221 shares during the period. BNP Paribas Arbitrage SA owned 0.05% of Meridian Bioscience worth $316,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of VIVO. Vanguard Group Inc. boosted its holdings in shares of Meridian Bioscience by 9.1% during the second quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock worth $63,299,000 after purchasing an additional 334,480 shares during the period. Intrinsic Edge Capital Management LLC purchased a new stake in shares of Meridian Bioscience during the second quarter worth about $4,618,000. Dimensional Fund Advisors LP boosted its holdings in shares of Meridian Bioscience by 16.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,667,971 shares of the company’s stock worth $26,271,000 after purchasing an additional 240,143 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Meridian Bioscience by 280.6% during the second quarter. Prudential Financial Inc. now owns 273,330 shares of the company’s stock worth $4,305,000 after purchasing an additional 201,519 shares during the period. Finally, State Street Corp boosted its holdings in shares of Meridian Bioscience by 15.2% during the first quarter. State Street Corp now owns 1,243,847 shares of the company’s stock worth $17,164,000 after purchasing an additional 163,770 shares during the period. Institutional investors own 87.01% of the company’s stock.
Several brokerages have commented on VIVO. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th. Canaccord Genuity restated a “hold” rating and issued a $14.00 price objective on shares of Meridian Bioscience in a report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Meridian Bioscience presently has a consensus rating of “Hold” and an average target price of $11.50.
Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.15. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.03%. The business had revenue of $49.70 million during the quarter, compared to the consensus estimate of $48.28 million. During the same quarter last year, the firm earned $0.14 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. equities analysts anticipate that Meridian Bioscience Inc. will post 0.66 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Monday, November 20th were paid a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date of this dividend was Friday, November 17th. Meridian Bioscience’s dividend payout ratio is 98.04%.
WARNING: “BNP Paribas Arbitrage SA Has $316,000 Holdings in Meridian Bioscience Inc. (VIVO)” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/12/bnp-paribas-arbitrage-sa-has-316000-holdings-in-meridian-bioscience-inc-vivo.html.
Meridian Bioscience Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.